Literature DB >> 20872191

Myoblast transplantation: a possible surgical treatment for a severe pediatric disease.

Beniamino Palmieri1, Jacques P Tremblay.   

Abstract

Duchenne muscular dystrophy (DMD) is a genetic X-linked recessive orphan disease that affects approximately 1 in 3 500 male births. Boys with DMD have progressive and predictable muscle destruction due to the absence of dystrophin, a protein present under the muscle fiber membrane. This absence induces contraction-related membrane damage and activation of inflammatory necrosis and fibrosis, leading to cardiac/diaphragmatic failure and death. The authors support the therapeutic role of myoblast transplantation in DMD, and describe the history and rationale for such an approach.

Entities:  

Mesh:

Year:  2010        PMID: 20872191      PMCID: PMC7087795          DOI: 10.1007/s00595-009-4242-z

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  55 in total

Review 1.  Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex.

Authors:  Basil J Petrof
Journal:  Am J Phys Med Rehabil       Date:  2002-11       Impact factor: 2.159

2.  Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy.

Authors:  Zejing Wang; James M Allen; Stanley R Riddell; Paul Gregorevic; Rainer Storb; Stephen J Tapscott; Jeffrey S Chamberlain; Christian S Kuhr
Journal:  Hum Gene Ther       Date:  2007-01       Impact factor: 5.695

3.  The fate of individual myoblasts after transplantation into muscles of DMD patients.

Authors:  E Gussoni; H M Blau; L M Kunkel
Journal:  Nat Med       Date:  1997-09       Impact factor: 53.440

4.  Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.

Authors:  S I Hodgetts; M D Grounds
Journal:  Immunol Cell Biol       Date:  2001-06       Impact factor: 5.126

5.  Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study.

Authors:  R G Miller; K R Sharma; G K Pavlath; E Gussoni; M Mynhier; A M Lanctot; C M Greco; L Steinman; H M Blau
Journal:  Muscle Nerve       Date:  1997-04       Impact factor: 3.217

6.  Central tolerance to myogenic cell transplants does not include muscle neoantigens.

Authors:  Geoffrey Camirand; Lionel Stéphan; Joël Rousseau; Mélanie K Sackett; Nicolas J Caron; Philippe Mills; Josef Kurtz; Megan Sykes; David M Rothstein; Jacques P Tremblay
Journal:  Transplantation       Date:  2008-06-27       Impact factor: 4.939

7.  Myoblast transfer in the treatment of Duchenne's muscular dystrophy.

Authors:  J R Mendell; J T Kissel; A A Amato; W King; L Signore; T W Prior; Z Sahenk; S Benson; P E McAndrew; R Rice
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

8.  Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients.

Authors:  P Atkison; G Joubert; A Barron; D Grant; K Paradis; E Seidman; W Wall; H Rosenberg; J Howard; S Williams
Journal:  Lancet       Date:  1995-04-08       Impact factor: 79.321

Review 9.  Calcineurin inhibitors in pediatric renal transplant recipients.

Authors:  Guido Filler
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

10.  Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects.

Authors:  A Asante-Korang; G J Boyle; S A Webber; S A Miller; F J Fricker
Journal:  J Heart Lung Transplant       Date:  1996-04       Impact factor: 10.247

View more
  2 in total

Review 1.  Genome engineering: a new approach to gene therapy for neuromuscular disorders.

Authors:  Christopher E Nelson; Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Nat Rev Neurol       Date:  2017-09-29       Impact factor: 42.937

Review 2.  Generation of skeletal muscle cells from embryonic and induced pluripotent stem cells as an in vitro model and for therapy of muscular dystrophies.

Authors:  Sabrina Salani; Chiara Donadoni; Federica Rizzo; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.